Did raloxifene reduce the incidence of lobular carcinoma in situ or ductal carcinoma in situ (non-invasive breast cancers)?
Not initially, but with longer followup, raloxifene seems to have some effect on these diagnoses. Tamoxifen has been shown to reduce the incidence of lobular carcinoma in situ (LCIS) and ductal carcinoma in situ (DCIS) by half. (LCIS and DCIS are sometimes called noninvasive or stage 0 breast cancers.) At 81 months, among the 9,736 women in the tamoxifen group, 111 developed LCIS or DCIS, compared to 137 of 9,754 women in the raloxifene group. This means that raloxifene reduces risk of non-invasive breast cancer by about 38 percent compared to tamoxifen reducing risk for this type of cancer by about 50 percent; or raloxifene is about 78 percent as effective as tamoxifen in reducing the risk of noninvasive breast cancer over almost 7 years. • How many participants developed uterine cancer? In STAR, more than half of the women entered the trial having had a hysterectomy. Women without a uterus are not at risk of uterine cancer. For those women in the trial with a uterus, the women in the
Related Questions
- What is the difference between invasive ductal carcinoma and ductal carcinoma in situ (DCIS) of the breast and how are they treated?
- Did raloxifene reduce the incidence of lobular carcinoma in situ or ductal carcinoma in situ (non-invasive breast cancers)?
- Have you ever had breast cancer, lobular carcinoma in situ or atypical ductal hyperplasia?